NCT06291207CompletedPhase 3
A Study to Evaluate the Efficacy and Safety of AD-224
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential Hypertension
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of AD-224
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 254 (actual)
- First submitted
- 27 Feb 2024
- Start date
- Apr 2024
- Primary completion date
- Apr 2025
- Lead sponsor
- Addpharma Inc.
- Diseases
- High blood pressure
- NCT number
- NCT06291207
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 254
- From Apr 2024 to the primary completion date, Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with Secondary Hypertension
Other
- Other exclusions applied
Who the study is looking for
- Signed informed consent
- Patients with Essential Hypertension
- Other inclusions applied
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.